A novel missense mutation in the HSD3B2 gene, underlying nonsalt-wasting congenital adrenal hyperplasia. new insight into the structure-function relationships of 3β-hydroxysteroid dehidrogenase type II.

CONTEXT 3βHSD2 is a bifunctional microsomal NAD+-dependent enzyme crucial for adrenal and gonad steroid biosynthesis, converting Δ5-steroids to Δ4-steroids. 3βHSD2 deficiency is a rare cause of congenital adrenal hyperplasia caused by recessive loss-of-function HSD3B2 mutations. OBJECTIVE The aim was to define the pathogenic consequences of a novel missense mutation in the HSD3B2 gene. PATIENT We report a 7-month-old 46,XX girl referred because of precocious pubarche and postnatal clitoromegaly. Hormonal profile showed inadequate glucocorticoid levels, increased 17OHP and renin levels, and very high DHEAS levels, suggestive of compensated nonsalt-losing 3βHSD2 deficiency. DESIGN AND RESULTS Direct sequencing revealed a novel, homozygous, pG250V HSD3B2 mutation. In vitro analysis in intact COS-7 cells showed impaired enzymatic activity for the conversion of pregnenolone to progesterone and dehydroepiandrosterone to androstenedione (20% and 27% of WT at 6 h, respectively). G250V-3βHSD2 decreased the Vmax for progesterone synthesis without affecting the Km for pregnenolone. Western blot and immunofluorescence suggested that p.G250V mutation has no effect on the expression and intracellular localization of the mutant protein. Molecular homology modeling predicted that mutant V250 affected an L239-Q251 loop next to a β-sheet structure in the NAD+-binding domain. CONCLUSIONS We identified a novel p.G250V mutation of HSD3B2 which causes an incomplete loss of enzymatic activity, explaining the compensated nonsalt loss phenotype. In vitro and in silico experiments provided insight into the structure-function relationship of the 3βHSD2 protein suggesting the importance of the L239-Q251 loop for the catalytic activity of the otherwise stable 3βHSD2 enzyme.

[1]  N. Mahdieh,et al.  In silico structural, functional and pathogenicity evaluation of a novel mutation: an overview of HSD3B2 gene mutations. , 2012, Gene.

[2]  Z. Hochberg,et al.  Increased activation of the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  W. Miller,et al.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. , 2011, Endocrine reviews.

[4]  R. Auchus,et al.  46,XX DSD: the masculinised female. , 2010, Best practice & research. Clinical endocrinology & metabolism.

[5]  V. Pletnev,et al.  Identification of Key Amino Acids Responsible for the Substantially Higher Affinities of Human Type 1 3β-Hydroxysteroid Dehydrogenase/Isomerase (3β-HSD1) for Substrates, Coenzymes, and Inhibitors Relative to Human 3β-HSD2* , 2005, Journal of Biological Chemistry.

[6]  Jacques Simard,et al.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. , 2005, Endocrine reviews.

[7]  Jacques Simard,et al.  Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family , 2005 .

[8]  W. Duax,et al.  Structure/Function Relationships Responsible for Coenzyme Specificity and the Isomerase Activity of Human Type 1 3β-Hydroxysteroid Dehydrogenase/Isomerase* , 2003, Journal of Biological Chemistry.

[9]  D. Balasubramanian,et al.  Mutations , 2003, Human Genetics.

[10]  B. Rich,et al.  A novel nonstop mutation in the stop codon and a novel missense mutation in the type II 3beta-hydroxysteroid dehydrogenase (3beta-HSD) gene causing, respectively, nonclassic and classic 3beta-HSD deficiency congenital adrenal hyperplasia. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  M. Forest,et al.  New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. , 1999, The Journal of clinical endocrinology and metabolism.

[12]  W L Miller,et al.  Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  S. Pang The Molecular and Clinical Spectrum of 3β-hydroxysteroid Dehydrogenase Deficiency Disorder , 1998, Trends in Endocrinology & Metabolism.

[14]  W. Nash,et al.  An NADH-induced Conformational Change That Mediates the Sequential 3β-Hydroxysteroid Dehydrogenase/Isomerase Activities Is Supported by Affinity Labeling and the Time-dependent Activation of Isomerase (*) , 1995, The Journal of Biological Chemistry.

[15]  J. Nakae,et al.  Molecular analysis of type II 3β-hydroxysteroid dehydrogenase gene in Japanese patients with classical 3β-hydroxysteroid dehydrogenase deficiency , 1995 .

[16]  J. Simard,et al.  MOLECULAR BASIS OF CONGENITAL ADRENAL HYPERPLASIA DUE TO 3β-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY , 1993, Pediatric Research.

[17]  M. Bettendorf,et al.  Male psuedohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  J. Simard,et al.  Structure and Expression of a New Complementary DNA Encoding the almost Exclusive 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4-lsomerase in Human Adrenals and Gonads , 1991 .

[19]  M. Dumont,et al.  Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. , 1991, Molecular endocrinology.

[20]  M. Volmer,et al.  Detection of 3 beta-hydroxysteroid-dehydrogenase deficiency by urinary steroid profiling: solvolysis of urinary samples should be a necessary prerequisite. , 1985, Clinica chimica acta; international journal of clinical chemistry.